12 January 2026 Experienced Ex-Hoffmann Eitle litigator who worked on Sanofi v Amgen joins firm’s growing UPC team in Germany.
12 January 2026
Latest Features
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Europe
A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.
Europe
The High Court’s ruling clarifies aspects of the SPC waiver but leaves unresolved questions relating to export-country rights and confidentiality, say Claire Phipps-Jones and Luke Norton of Bristows.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Europe
With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.
Big Pharma
Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Latest Conference Videos
Americas
Speakers from Greenberg Traurig, Verdiva Bio, Halozyme, and Metsera discuss the implications of the USPTO’s 2024 §112 guidelines on life sciences patents.
Europe
Amanda Simons, J A Kemp, explains how clinical research affects patentability in Europe and how clinical data can be used to strengthen protection.
Biotechnology
Dirk Buehler, Maiwald, discusses how the “try and see” standard is applied before the EPO and its relevance in pharma and biotech cases.
Europe
High-value IP disputes are reshaping life sciences litigation, with perspectives from McDermott Will & Emery, Curevac, Regeneron, HGF, and the UPC.
More News
7 January 2026 A Brussels-based partner, specialising in pharmaceuticals and biologics, jumps ship as a competitor firm continues to build out its EU healthcare regulatory bench.
7 January 2026 As he hands over the baton, Bobby Mukherjee reflects on his time leading the Chartered Institute of Patent Attorneys—from progressing the soon-to-be-launched paid apprenticeship schemes to engaging with the UK body’s in-house members. Sarah Speight reports.
6 January 2026 The new recruits from a boutique Boston firm enables Merchant to expand and strengthen its tech and life sciences offering in the innovation hub.
6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.
6 January 2026 As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.
5 January 2026 The firm brings in a former Plesner director and Novo Nordisk in-house counsel with regulatory and compliance expertise.
2 January 2026 With the unprecedented changes at the PTAB in 2025, what could the year ahead hold for the agency? Lawyers from Sterne Kessler explore.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox